(Total Views: 518)
Posted On: 05/19/2019 12:07:51 AM
Post# of 148984
BIT225's disruption of vpu inhibition is certainly intriguing and may be of benefit, but how effective is it?
Biotron's phase 2 trial results use sCD163 as their claim to superiority. If I'm reading the chart right there is a 38% decrease from baseline in sCD163. BIT225 Their other results don't seem that great.
There are no trials of leronlimab that I could find that use sCD163 as a test result. However Maraviroc had a 43% reduction in sCD163 in one of their tests. Maraviroc
Biotron's phase 2 trial results use sCD163 as their claim to superiority. If I'm reading the chart right there is a 38% decrease from baseline in sCD163. BIT225 Their other results don't seem that great.
There are no trials of leronlimab that I could find that use sCD163 as a test result. However Maraviroc had a 43% reduction in sCD163 in one of their tests. Maraviroc
(0)
(0)Scroll down for more posts ▼
